WASHINGTON — Medicare officials are still hammering out the technical specifics of how the massive program will start to negotiate drug prices — let alone the substantive ones, Medicare chief Meena Seshamani said at a STAT event Tuesday.
“There are operations that need to be stood up both on the [Medicare] side and on the manufacturer side,” she said, describing “monthly technical calls.” “Being able to vary policy and operations so that things can actually work on the ground is very important.”
Drug price negotiation is a significant new power for Medicare, and it’s a major undertaking for the program.
This article is exclusive to STAT+ subscribers
Unlock this article — plus daily intelligence on Capitol Hill and the life sciences industry — by subscribing to STAT+.
Already have an account? Log in
Already have an account? Log in
About the Author Reprints
To submit a correction request, please visit our Contact Us page.
STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect